Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-07-01

Clinical Trial Update: A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 study of dulaglutide in children and adolescents with type 2 diabetes completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dulaglutide (dulaglutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2022-07-01